Skip to main content
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. — Investor Relations & Filings

Ticker · VTVT ISIN · US9183852048 LEI · 549300WQE5EI9R35SE66 US Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-03-31 Investor Presentation
Country US United States of America
Listing US VTVT

About vTv Therapeutics Inc.

https://vtvtherapeutics.com/

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. The company's primary commitment is to improving the lives of patients with diabetes. Its lead clinical drug candidate is cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. In collaboration with development partners, vTv is also pursuing additional indications for its pipeline molecules, including type 2 diabetes and other chronic conditions.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2025, by vTv Therapeutics Inc. The key content is an updated slide presentation titled 'Investor Presentation dated March 2025' attached as Exhibit 99.1. The text explicitly states that the presentation is used in meetings with investors and analysts and may be updated over time. There are no financial statements or detailed financial data included in the text, only a reference to the presentation. The document length is 3794 characters, which is relatively short and consistent with an announcement-type filing rather than a full report. According to the rules, a Form 8-K with an attached investor presentation is classified as an Investor Presentation (IP).
2025-03-31 English
10-K
Annual Report FY 2024
2025-03-20 English
8-K
Report Publication Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 20, 2025, by vTv Therapeutics Inc. It announces the issuance of a press release reporting financial results for the fiscal year ended December 31, 2024. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference, and that the information is not "filed" for purposes of Section 18 of the Exchange Act. The document itself does not contain the full financial results or detailed financial statements but rather announces their release. The document length is 3720 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of a report, not the report itself. Therefore, the correct classification is Report Publication Announcement (RPA).
2025-03-20 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about the FDA lifting a clinical hold on a program, attached as an exhibit. The document length is 3274 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-03-17 English
FORM 4
Director's Dealing
2025-03-07 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the resignation announcement of the Executive Vice President and CFO, Steven Tuch, effective March 21, 2025. The document specifically falls under Item 5.02, which relates to departure or election of directors or certain officers. There is no financial data or detailed management discussion, nor is it an earnings release or annual report. The document is not a proxy statement or voting result announcement. It is clearly an announcement of a management change, which fits the Board/Management Information (MANG) category. The document length is 3415 characters, which is typical for an 8-K filing of this nature. Therefore, the classification is MANG with high confidence.
2025-02-27 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.